Intervacc AB (IVACC) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -55.97%, its profits have risen by 30.6%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 307 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.62

Return on Equity

-21.92%

Price to Book

0.94

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.72%

6 Months

-16.89%

1 Year

-57.91%

2 Years

-87.61%

3 Years

-95.91%

4 Years

-98.12%

5 Years

-97.42%

Intervacc AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

25.62%

EBIT Growth (5y)

-190.98%

EBIT to Interest (avg)

-60.75

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.63

Sales to Capital Employed (avg)

0.05

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.10

EV to EBIT

-2.12

EV to EBITDA

-2.83

EV to Capital Employed

1.27

EV to Sales

8.58

PEG Ratio

Dividend Yield

ROCE (Latest)

-60.09%

ROE (Latest)

-21.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 52.17% vs 12.20% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -34.85% vs 27.07% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.00",
          "val2": "4.60",
          "chgp": "52.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.90",
          "val2": "-9.50",
          "chgp": "-46.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.80",
          "val2": "-13.20",
          "chgp": "-34.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,642.50%",
          "val2": "-3,096.00%",
          "chgp": "45.35%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 47.50% vs -17.53% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 26.63% vs -60.28% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.80",
          "val2": "8.00",
          "chgp": "47.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-76.50",
          "val2": "-87.60",
          "chgp": "12.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-75.50",
          "val2": "-102.90",
          "chgp": "26.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,595.30%",
          "val2": "-11,811.60%",
          "chgp": "521.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

7.00

4.60

52.17%

Operating Profit (PBDIT) excl Other Income

-13.90

-9.50

-46.32%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.80

-13.20

-34.85%

Operating Profit Margin (Excl OI)

-2,642.50%

-3,096.00%

45.35%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 52.17% vs 12.20% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -34.85% vs 27.07% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

11.80

8.00

47.50%

Operating Profit (PBDIT) excl Other Income

-76.50

-87.60

12.67%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-75.50

-102.90

26.63%

Operating Profit Margin (Excl OI)

-6,595.30%

-11,811.60%

521.63%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 47.50% vs -17.53% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 26.63% vs -60.28% in Dec 2023

All Annual Results

Company CV

About Intervacc AB

Intervacc AB

Pharmaceuticals & Biotechnology

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Company Coordinates

Company Details

Vastertorpsvagen 135 , HAGERSTEN None : 129 44

Tel: 46 8 12010600

http://intervacc.se/

Registrar Details